公开(公告)号：US20230293687A1

公开(公告)日：2023-09-21

申请号：US18017628

申请日：2021-07-29

申请人： Eureka Therapeutics, Inc.

发明人： Cheng Liu ,  Hongbing Zhang ,  Zhiyuan Yang ,  Pengbo Zhang ,  Yixiang Xu ,  Guangyuan Xiong ,  Ziyou Cui

IPC分类号： A61K39/00 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C07K14/47 ,  C07K14/005 ,  C07K16/30 ,  C07K16/08 ,  C07K16/18 ,  C07K14/435 ,  C07K16/32 ,  C07K16/40 ,  C07K14/78 ,  C07K14/82 ,  C07K16/44 ,  C07K14/71 ,  C07K14/73 ,  C07K14/735 ,  A61P35/00

CPC分类号： A61K39/4622 ,  C12N15/86 ,  C07K14/7051 ,  C07K14/70578 ,  A61K39/4632 ,  A61K39/464417 ,  C07K14/70521 ,  C07K14/70553 ,  C07K14/70507 ,  C07K14/70503 ,  C07K14/7056 ,  C07K14/705 ,  A61K39/464411 ,  A61K39/464402 ,  A61K39/4644 ,  A61K39/4633 ,  C07K16/28 ,  C07K14/4748 ,  C07K14/005 ,  A61K39/464489 ,  A61K39/464481 ,  A61K39/464453 ,  A61K39/464414 ,  A61K39/464406 ,  C07K16/3038 ,  C07K16/303 ,  C07K16/30 ,  C07K16/2833 ,  C07K16/084 ,  A61K39/464838 ,  C07K16/18 ,  A61K39/4643 ,  C07K14/435 ,  C07K16/3069 ,  A61K39/464494 ,  C07K16/32 ,  C07K16/40 ,  C07K14/78 ,  A61K39/464454 ,  A61K39/464462 ,  C07K16/3053 ,  C07K14/70596 ,  C07K16/2896 ,  A61K39/46432 ,  A61K39/464488 ,  A61K39/464486 ,  A61K39/464449 ,  A61K39/464451 ,  C07K14/4746 ,  C07K16/3015 ,  C07K14/82 ,  C07K16/44 ,  A61K39/4645 ,  C07K14/4727 ,  C07K16/3092 ,  C07K14/71 ,  C07K16/2863 ,  A61K39/464431 ,  A61K39/464495 ,  A61K39/46441 ,  C07K14/70589 ,  A61K39/464413 ,  C07K14/70514 ,  C07K14/70535 ,  C07K14/70532 ,  A61K39/4611 ,  A61K39/4613 ,  A61P35/00 ,  C12N2740/15043 ,  C07K2319/03 ,  C07K2319/033 ,  C07K2319/035 ,  C07K2317/569 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/565

摘要： Described herein are immune cells comprising: a T-cell receptor (TCR) and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or components thereof (e.g., the CSR) for therapeutic treatment of cancers (e.g., solid tumor cancers).

公开(公告)号：US20220323497A1

公开(公告)日：2022-10-13

申请号：US17628120

申请日：2020-07-24

申请人： Eureka Therapeutics, Inc.

发明人： Hongruo YUN ,  Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Lucas Horan ,  Shaohua Xu ,  Guangyan Xiong ,  Shan Li ,  Yixiang Xu ,  Bradley Austin Heller ,  Hongbing Zhang ,  Hong Liu

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

摘要： Described herein are immune cells comprising: a chimeric antigen receptor (CAR) that comprises (i) an extracellular target-binding domain comprising an antibody moiety; (ii) a transmembrane domain; and (iii) a primary signaling domain, and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or compositions thereof for therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers).